UCLA Health joins nationwide clinical trial for acute myeloid leukemia
UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save more lives.Acute myeloid leukemia, which affects 20,000 Americans annually, is responsible for more than 10,000 deaths a year, making it the most lethal form of blood cancer. “The ability to quickly connect patients with investigational drug therapies based on the individual genetic markers of their disease is the essence of precision medicine,” said Dr. Gary Schiller, the principal investigator in the UCLA arm of the trial and a member of theUCLA Jonsson Comprehensive Cancer Center. “We hope that this becomes a turning point in how we treat this disease, which is, in many ways, multiple diseases with multiple mutations involved.”The trial — for people 60 and older who are newly diagnosed with acute myeloid leukemia — is sponsored by the Leukemia&Lymphoma Society and is divided into nine treatment arms based on ...
Conclusions: These results suggest that JAK/STAT3 and NF-κB signals play important roles in ATC-CSCs. Targeting these signaling pathways may be a promising approach to treat ATC. PMID: 30784360 [PubMed - as supplied by publisher]
The deal comes four months after Immune Design Corp. halted its lead cancer vaccine trial and restructured its drug development plans.
Geoffrey Turner, 66, of Latham, New York, passed away on February 13 after a three-month battle with lung cancer. His self-deprecating obituary appeared in the Albany Times-Union on Saturday.
Authors: De Luca L, Laurenzana I, Trino S, Lamorte D, Caivano A, Musto P Abstract INTRODUCTION: Multiple myeloma (MM) is characterized by a clonal proliferation of neoplastic plasma cells (PCs) in bone marrow (BM) and the interplay between MM PCs and the BM microenvironment, which plays a relevant role in its pathogenesis. In this important cross-talk, extracellular vesicles (EVs) are active. EVs, including small and medium/large EVs, are lipid bi-layer particles released in circulation by normal and neoplastic cells. A selected cargo of lipids, proteins, and nucleic acids is loaded into EVs, and delivered locally ...
Investigational agent sacituzumab govitecan showed activity in patients with metastatic urothelial cancer, including some previously treated with immune checkpoint inhibitors.Medscape Medical News
We report means and 95% uncertainty intervals (UIs) for incidence, mortality, and disability-adjusted life-years (DALYs) estimates for CNS cancers (according to the International Classification of Diseases tenth revision: malignant neoplasm of meninges, malignant neoplasm of brain, and malignant neoplasm of spinal cord, cranial nerves, and other parts of CNS) from the Global Burden of Diseases, Injuries, and Risk Factors Study 2016. Data sources include vital registration and cancer registry data. Mortality was modelled using an ensemble model approach. Incidence was estimated by dividing the final mortality estimates by m...
Authors: Adamo B, Ricciardi GRR, Ieni A, Franchina T, Fazzari C, Sanò MV, Angelico G, Caruso M, Tuccari G, Adamo V Abstract [This corrects the article DOI: 10.18632/oncotarget.20293.]. PMID: 30783520 [PubMed - in process]
Conclusions: We report a high rate of guideline-driven care for AYAs with acute leukemia and lymphoma seen by a multidisciplinary team solely focused on AYA care delivery within a community practice setting. Metrics are derived from best practices from both pediatric (pediatric inspired therapy in AML, ALL; sedation for procedures) and adult (ABVD for HL, NCI and pharma-sponsored trials) oncology paradigms. Immersive AYA programs in non-academic settings are potentially effective models of reducing health disparities and improving outcomes in AYAs.Table 1.DisclosuresCrosswell: Seattle Genetics: Other: stock ownership in Seattle Genetics.
Acute Myeloid Leukemia (AML) is an aggressive malignancy that is treated using intensive cytotoxic chemotherapeutic regimens. There are limited alternative therapeutic options once the disease becomes refractory to chemotherapeutic treatment. CD33 is expressed on the surface of the vast majority of AML blasts and cells in chronic myeloid leukemia-blast crisis (CML-BC) – and is a well-validated immunotherapeutic target. CD33 is also aberrantly expressed on a subset of T cell acute lymphoblastic leukemias (ALLs). Normal tissue expression is restricted to normal myeloid cells. Treatment of pre-B cell ALL and lymph...
Conclusion This is the first attempt to provide a glimpse on the pattern and distribution of HMs among AYA in Bangladesh. Future studies are essential to get a better insight on the epidemiology, biology, potential risk factors and treatment outcomes for the AYA age group.
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Cancer Therapy | Child Development | Children | Clinical Trials | Food and Drug Administration (FDA) | Gene Therapy | Genetics | Hematology | Hospitals | Learning | Leukemia | Lymphoma | Research | Universities & Medical Training